viewBioSig Technologies, Inc.

BioSig Technologies to feature its PURE EP System at complex arrhythmias symposium EPLive 2020

BioSig Technologies said its PURE EP technology will be featured in several live cases with expert commentary that will serve as the primary teaching tool

BioSig Technologies, Inc. -
BioSig Technologies says more than 350 patient cases have been completed with the PURE EP System to date

BioSig Technologies, Inc (NASDAQ:BSGM) reported that its PURE EP technology will be featured in several live cases broadcast during EPLive 2020, the fifth international symposium on complex arrhythmias.

The company said a total of 21 live and 13 recorded cases will broadcast from the Electrophysiology Center at St. David’s Medical Center in Austin, Texas, with expert commentary that will serve as the primary teaching tool.

BioSig Technologies CEO Kenneth Londoner said in a statement:  “We are thrilled to be included in EPLive, a very unique physician education event, and we appreciate all the effort that went into making this important conference a reality amidst the global pandemic. We are grateful to Dr. Natale and his colleagues at TCAI for the outstanding support they continue to provide to our team and to the entire faculty of EPLive for their dedication to improving patient outcomes through the introduction of sophisticated educational tools and techniques for the benefit of the global physician audience.”

READ: BioSig Technologies looking to unlock the future of bioelectronic medicine

BioSig’s PURE EP System designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals, elevating the standard of care in electrophysiology through enhanced signal acquisition, digital signal processing, and analysis.

PURE EP will be highlighted in several patient cases conducted live by Andrea Natale, executive medical director of TCAI, and EPLive course director, and Joseph Gallinghouse, MD,  as part of a two-day educational meeting for practicing clinical cardiac electrophysiologists, electrophysiology fellows, and general cardiologists at the Texas Cardiac Arrhythmia Institute from December 3 to December 4, 2020.

The company noted that more than 350 patient cases have been completed with the PURE EP System to date by 25 electrophysiologists across several clinical sites. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center was the first clinical installation site for the evaluation of BioSig’s PURE EP System. 

BioSig Technologies expects its advanced signal processing solutions will unlock the future of bioelectronic medicine, a rapidly-growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. 

Contact Sean at [email protected]

Quick facts: BioSig Technologies, Inc.

Price: 4.78 USD

Market: NASDAQ
Market Cap: $146.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...


BioSig Technologies installs PURE EP System at Memorial Hospital,...

BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the group's PURE EP System has been installed and first patient cases conducted at Memorial Hospital of South Bend, part of Beacon Health System in South Bend, Indiana. Londoner says this represents the seventh...

6 days, 14 hours ago

2 min read